$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417027501 Filed on May 15, 2017

Income Statement

Concept	2017 Q2	2016 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$990.0K	$980.0K
YoY Change	11.24%	63.33%
% of Gross Profit
Research & Development	$1.260M	$1.067M
YoY Change	-21.25%	95.35%
% of Gross Profit
Depreciation & Amortization	$160.0K	$163.5K
YoY Change	0.0%	218.54%
% of Gross Profit
Operating Expenses	$2.250M	$1.067M
YoY Change	-10.0%	-4.91%
Operating Profit
YoY Change
Interest Expense	-$90.00K	$301.1K
YoY Change	-107.32%	-84.32%
% of Operating Profit
Other Income/Expense, Net	-$220.0K	-$2.943M
YoY Change	-42.11%	-437.7%
Pretax Income	-$2.560M	-$4.992M
YoY Change	55.15%	1888.57%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.560M	-$4.992M
YoY Change	55.15%	1888.57%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.09
Diluted Earnings Per Share	-$812.7K	-$0.09
COMMON SHARES
Basic Shares Outstanding	63.07M shares	57.84M shares
Diluted Shares Outstanding		57.84M shares

Balance Sheet

Concept	2017 Q2	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.10M	$25.60M
YoY Change	-37.5%	-24.53%
Cash & Equivalents	$15.10M	$25.60M
Short-Term Investments
Other Short-Term Assets	$190.0K	$310.0K
YoY Change	-13.64%
Inventory
Prepaid Expenses	$190.2K	$314.5K
Receivables
Other Receivables
Total Short-Term Assets	$15.29M	$25.91M
YoY Change	-37.29%	-24.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.27M	$11.90M
YoY Change	-4.16%	9.09%
Goodwill
YoY Change
Intangibles	$383.2K
YoY Change	-2.11%
Long-Term Investments
YoY Change
Other Assets	$60.00K	$120.0K
YoY Change	-40.0%
Total Long-Term Assets	$11.71M	$12.41M
YoY Change	-4.4%	9.71%
TOTAL ASSETS
Total Short-Term Assets	$15.29M	$25.91M
Total Long-Term Assets	$11.71M	$12.41M
Total Assets	$27.00M	$38.32M
YoY Change	-26.29%	-15.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$480.0K	$450.0K
YoY Change	-44.19%	2150.0%
Accrued Expenses	$34.00K	$78.37K
YoY Change	-4.49%	-37.33%
Deferred Revenue
YoY Change
Short-Term Debt	$3.960M	$5.270M
YoY Change	-27.61%
Long-Term Debt Due		$5.271M
YoY Change
Total Short-Term Liabilities	$4.666M	$6.619M
YoY Change	-30.82%	1164.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$2.960M
YoY Change	-100.0%
Other Long-Term Liabilities	$2.020M	$4.760M
YoY Change	-45.55%	-25.04%
Total Long-Term Liabilities	$2.015M	$7.716M
YoY Change	-70.54%	-41.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.666M	$6.619M
Total Long-Term Liabilities	$2.015M	$7.716M
Total Liabilities	$6.681M	$14.34M
YoY Change	-50.82%	4.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.13M	-$63.17M
YoY Change	15.9%	18.79%
Common Stock	$63.31K
YoY Change	8.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.32M	$23.98M
YoY Change
Total Liabilities & Shareholders Equity	$27.00M	$38.32M
YoY Change	-26.29%	-15.97%

Cashflow Statement

Concept	2017 Q2	2016 Q1
OPERATING ACTIVITIES
Net Income	-$2.560M	-$4.992M
YoY Change	55.15%	1888.57%
Depreciation, Depletion And Amortization	$160.0K	$163.5K
YoY Change	0.0%	218.54%
Cash From Operating Activities	-$1.010M	-$2.580M
YoY Change	-26.81%	23.44%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$60.00K
YoY Change	-33.33%	-76.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$40.00K	-$60.00K
YoY Change	-33.33%	-108.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-1.010M	-2.580M
Cash From Investing Activities	-40.00K	-60.00K
Cash From Financing Activities	0.000	0.000
Net Change In Cash	-1.050M	-2.640M
YoY Change	-27.08%	97.01%
FREE CASH FLOW
Cash From Operating Activities	-$1.010M	-$2.580M
Capital Expenditures	-$40.00K	-$60.00K
Free Cash Flow	-$970.0K	-$2.520M
YoY Change	-26.52%	36.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2810071	shares
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	43378	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	1124411	USD
	us-gaap	Interest Expense InterestExpense	655767	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4272339	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3427068	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2936510	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7353781	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6363578	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	43870	USD
	us-gaap	Interest Expense InterestExpense	791115	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	1046663	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1676093	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	56115	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-392739	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2710338	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7746520	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9073916	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7746520	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9073916	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-915938	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	1101661	USD
	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	81000	USD
	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	32462	USD
	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	33750	USD
	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	440512	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	143050	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	196895	USD
	us-gaap	Depreciation Depreciation	488997	USD
	us-gaap	Depreciation Depreciation	489330	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6202	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6201	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-915938	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	100064	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5447105	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6888480	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5871372	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8007100	USD
	us-gaap	Interest Paid InterestPaid	791115	USD
	us-gaap	Interest Paid InterestPaid	492434	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31467748	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25596376	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1124411	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1046663	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	16668	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	49854	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-125000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-125001	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1676093	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2177	USD
	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	313	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	118620	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	424267	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	32462	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	29422	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	1101661	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	547946	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	16182	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-17657	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-767454	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	64669	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-37752	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-27341	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-440512	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-493334	USD
	nnvc	Depreciation Due To Decommissioning Of Fixed Assets DepreciationDueToDecommissioningOfFixedAssets	0	USD
	nnvc	Depreciation Due To Decommissioning Of Fixed Assets DepreciationDueToDecommissioningOfFixedAssets	332476	USD
	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6599552	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6662428	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.09
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3138677	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4991671	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3138677	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4991671	USD
CY2017Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2016Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.09
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.16
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7746520	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9073916	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.16
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7746520	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9073916	USD
CY2016Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2017Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	5000000	USD
CY2016Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2017Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2016Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	46897	USD
CY2017Q1	nnvc	Office Equipment Gross OfficeEquipmentGross	48486	USD
CY2016Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2017Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2016Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5302677	USD
CY2017Q1	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5419708	USD
CY2017Q1	us-gaap	Land Land	260000	USD
CY2016Q2	us-gaap	Land Land	260000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	163611	USD
CY2016Q1	us-gaap	Depreciation Depreciation	163511	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	391467	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	385266	USD
CY2017Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	655763	USD
CY2017Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	597694	USD
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2479935	shares
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	75000	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	NANOVIRICIDES, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001379006
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Trading Symbol TradingSymbol	NNVC
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63072000	shares
CY2016Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	0	USD
CY2017Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	370187	USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63072333	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63072333	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58179699	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58179699	shares
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332524	USD
CY2016Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332524	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	nnvc	Common Stock Issued During Period Employee Stock Compensation Value Issued CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued	82145	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5332524	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	370187	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5000000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <b><font style="FONT-SIZE: 10pt">Note 1 - Organization and Nature of Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">NanoViricides, Inc. was incorporated under the laws of the State of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Colorado</font> on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 25, 2000</font> as <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Edot-com.com</font>, Inc<b>.</b> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired NanoViricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  NanoViricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s Common Stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECMM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> NanoViricides, Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. Under the License Agreements, TheraCour Pharma will receive a royalty upon sale of resulting products from NanoViricides. There is no royalty payable to date. For further details, see Note 4.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(adjusted for the 3.5 to 1 reverse split)</font> of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Series A Preferred Stock is convertible, only in the event of a “change of control” of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock. </font>  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The 2,000,000 shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	332524	USD
	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common stock (the Redemption Warrants, and collectively with (i) (iv), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	charge its costs (direct and indirect) plus no more than 30% of a certain portion of direct costs
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	71430	shares
	nnvc	Noncashcompensationexpenses Noncashcompensationexpenses	82145	USD
CY2017Q1	nnvc	Conversion Price Of Shares Converted ConversionPriceOfSharesConverted	1.1533
CY2017Q1	us-gaap	Interest Payable Current InterestPayableCurrent	27178	USD
CY2017Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	24266	USD
CY2017Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	71430	shares
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.23
CY2017Q1	nnvc	Noncashcompensationexpenses Noncashcompensationexpenses	82145	USD
CY2017Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	5332524	USD

Files In Submission

Name	View Source	Status
0001144204-17-027501-index-headers.html	Edgar Link	pending
0001144204-17-027501-index.html	Edgar Link	pending
0001144204-17-027501.txt	Edgar Link	pending
0001144204-17-027501-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20170331.xml	Edgar Link	completed
nnvc-20170331.xsd	Edgar Link	pending
nnvc-20170331_cal.xml	Edgar Link	unprocessable
nnvc-20170331_def.xml	Edgar Link	unprocessable
nnvc-20170331_lab.xml	Edgar Link	unprocessable
nnvc-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v466096_10q.htm	Edgar Link	pending
v466096_ex31-1.htm	Edgar Link	pending
v466096_ex31-2.htm	Edgar Link	pending
v466096_ex32-1.htm	Edgar Link	pending
v466096_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2017 Q2 Form 10-Q Financial Statement

#000114420417027501 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2017 Q2 Form 10-Q Financial Statement

#000114420417027501 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc